Targeting complement cascade: an alternative strategy for COVID-19.

Area of Science:

• Immunology
• Virology
• Pathology

Background:

• The complement system is integral to innate and adaptive immunity, mediating defense through complex enzymatic cascades.
• Dysregulation of complement activation can trigger cytokine storms, inflammation, and tissue damage, leading to acute respiratory distress syndrome (ARDS).
• Similar pathological mechanisms involving complement activation are observed in viral infections like MERS, SARS, and COVID-19.

Purpose of the Study:

• To investigate the role of complement system activation in the pathogenesis of COVID-19.
• To explore the therapeutic potential of complement inhibitors in mitigating lung inflammation and ARDS associated with COVID-19.

Main Methods:

• Review of existing literature on complement system activation in viral infections, including COVID-19.
• Analysis of pre-clinical and clinical studies on the effects of complement inhibition.
• Examination of complement component deposition in animal models and autopsy samples of COVID-19 patients.

Main Results:

• Complement activation, particularly via the lectin pathway involving MASP2, is implicated in COVID-19 pathogenesis.
• Evidence suggests complement component deposition in lung tissues of COVID-19 patients.
• Inhibition of complement components has shown promise in reducing tissue damage and aiding recovery in ARDS models.

Conclusions:

• Targeting the complement cascade and employing complement inhibitors represent a promising therapeutic strategy for managing COVID-19.
• Reducing complement-mediated lung inflammation could be crucial for treating severe respiratory complications associated with SARS-CoV-2 infection.